Evommune (EVMN) Short-term Investments (2024 - 2026)

Evommune (EVMN) has 3 years of Short-term Investments data on file, last reported at $163.1 million in Q1 2026.

• Quarterly Short-term Investments changed N/A year-over-year to $163.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163.1 million (changed N/A YoY) and the FY2025 annual result came in at $105.1 million, up 88.47% from the prior year.
• Short-term Investments grew to $163.1 million in Q1 2026 per EVMN's latest filing, from $105.1 million in the prior quarter.
• Across five years, Short-term Investments topped out at $163.1 million in Q1 2026 and bottomed at $49.2 million in Q3 2025.
• The 3-year median for Short-term Investments is $80.5 million (2024), against an average of $93.3 million.
• Peak annual rise in Short-term Investments reached 88.47% in 2025, while the deepest fall reached 88.47% in 2025.
• Tracing EVMN's Short-term Investments over 3 years: stood at $55.8 million in 2024, then jumped by 88.47% to $105.1 million in 2025, then soared by 55.17% to $163.1 million in 2026.
• Per Business Quant, the three latest EVMN Short-term Investments figures stand at $163.1 million (Q1 2026), $105.1 million (Q4 2025), and $49.2 million (Q3 2025).

Peer Comparison